Evidence map›Paper›PMID 23077670›Full record

ArticlePloS one2012

Pleiotrophin (PTN) expression and function and in the mouse mammary gland and mammary epithelial cells.

Sonia M Rosenfield, Emma T Bowden, Shani Cohen-Missner, Krissa A Gibby, Virginie Ory, Ralf T Henke, Anna T Riegel, Anton Wellstein

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Decorin: matrix-based pan-cancer tumor suppressor.Molecular and cellular biochemistry · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Pleiotrophin: Activity and mechanism.Advances in clinical chemistry · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Sonia M RosenfieldLombardi Cancer Center, Georgetown University, Washington, District of Columbia, United States of America.
Emma T Bowden
Shani Cohen-Missner
Krissa A Gibby
Virginie Ory
Ralf T Henke
Anna T Riegel
Anton Wellstein
Georgetown University Medical Center · USGeorgetown University · US

Funding

TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
SPORE IN BREAST CANCERP50CA058185 · NCI · GEORGETOWN UNIVERSITY · PI DICKSON, ROBERT B. · 1992 to 2004
$4.0M
Inhibition of the ALK Receptor KinaseR01CA101811 · NCI · GEORGETOWN UNIVERSITY · PI WELLSTEIN, ANTON · 2003 to 2006
$1.6M
NCI NIH HHS P50 CA058185NCI NIH HHS R01 CA101811NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

Expression of the heparin-binding growth factor, pleiotrophin (PTN) in the mammary gland has been reported but its function during mammary gland development is not known. We examined the expression of PTN and its receptor ALK (Anaplastic Lymphoma Kinase) at various stages of mouse mammary gland development and found that their expression in epithelial cells is regulated in parallel during pregnancy. A 30-fold downregulation of PTN mRNA expression was observed during mid-pregnancy when the mammary gland undergoes lobular-alveolar differentiation. After weaning of pups, PTN expression was restored although baseline expression of PTN was reduced significantly in mammary glands of mice that had undergone multiple pregnancies. We found PTN expressed in epithelial cells of the mammary gland and thus used a monoclonal anti-PTN blocking antibody to elucidate its function in cultured mammary epithelial cells (MECs) as well as during gland development. Real-time impedance monitoring of MECs growth, migration and invasion during anti-PTN blocking antibody treatment showed that MECs motility and invasion but not proliferation depend on the activity of endogenous PTN. Increased number of mammospheres with laminin deposition after anti-PTN blocking antibody treatment of MECs in 3D culture and expression of progenitor markers suggest that the endogenously expressed PTN inhibits the expansion and differentiation of epithelial progenitor cells by disrupting cell-matrix adhesion. In vivo, PTN activity was found to inhibit ductal outgrowth and branching via the inhibition of phospho ERK1/2 signaling in the mammary epithelial cells. We conclude that PTN delays the maturation of the mammary gland by maintaining mammary epithelial cells in a progenitor phenotype and by inhibiting their differentiation during mammary gland development.

Indexed as

Carrier ProteinsCytokinesGene Expression RegulationAnaplastic Lymphoma KinaseAnimalsCell Culture TechniquesCell DifferentiationCell-Matrix JunctionsCells, CulturedEpithelial CellsFemaleHumansMammary Glands, AnimalMAP Kinase Signaling SystemPregnancyReceptor Protein-Tyrosine KinasesALK protein, humanAlk protein, mouseAnaplastic Lymphoma KinaseCarrier ProteinsCytokinespleiotrophinReceptor Protein-Tyrosine Kinases

Identifiers

PMID23077670
PMCPMC3471873
OpenAlexW1987785641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.